Falkson H C, Falkson G, Schoeman H S, Louw E M, Portugal M A
S Afr Med J. 1983 Jun 11;63(24):917-22.
Survival figures of women with operable breast cancer reached a plateau 40 years ago. It was only with the advent of adjuvant chemotherapy that these figures showed a dramatic improvement. Data obtained in 105 postmenopausal women with operable breast cancer, treated at our clinic, are presented. Patients with axillary node disease were treated on four different protocols: cyclophosphamide + methotrexate + fluoro-uracil (CMF) with or without immunotherapy was compared with CMF + vincristine + prednisone, while other studies compared observation only with CMF + prednisone and CMF + prednisone + tamoxifen. Patients older than 65 years received tamoxifen or placebo. Patient discriminants and treatment regimens are discussed. Results indicating that certain subsets of postmenopausal women definitely need adjuvant chemotherapy are presented. The literature is briefly reviewed and the motivation for our new studies explained.
40年前，可手术乳腺癌女性的生存率达到了平台期。直到辅助化疗出现，这些数据才显著改善。本文展示了在我们诊所接受治疗的105例绝经后可手术乳腺癌女性的数据。有腋窝淋巴结疾病的患者接受了四种不同方案的治疗：比较了环磷酰胺+甲氨蝶呤+氟尿嘧啶（CMF）联合或不联合免疫治疗与CMF+长春新碱+泼尼松，而其他研究则比较了单纯观察与CMF+泼尼松以及CMF+泼尼松+他莫昔芬。65岁以上的患者接受他莫昔芬或安慰剂治疗。讨论了患者判别因素和治疗方案。展示了表明某些绝经后女性亚组绝对需要辅助化疗的结果。简要回顾了文献并解释了我们开展新研究的动机。
